vs
Side-by-side financial comparison of Expensify, Inc. (EXFY) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
Expensify, Inc. is the larger business by last-quarter revenue ($35.2M vs $18.3M, roughly 1.9× ROCKWELL MEDICAL, INC.). On growth, Expensify, Inc. posted the faster year-over-year revenue change (-4.9% vs -25.6%). Over the past eight quarters, Expensify, Inc.'s revenue compounded faster (2.4% CAGR vs -10.1%).
Expensify, Inc. is a software company that develops an expense management system for personal and business use. Expensify also offers a business credit card called the Expensify Card.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
EXFY vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $18.3M |
| Net Profit | — | $-554.0K |
| Gross Margin | 49.2% | 21.1% |
| Operating Margin | -11.2% | -2.2% |
| Net Margin | — | -3.0% |
| Revenue YoY | -4.9% | -25.6% |
| Net Profit YoY | — | 26.7% |
| EPS (diluted) | $-0.07 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | $18.3M | ||
| Q3 25 | $35.1M | $15.9M | ||
| Q2 25 | $35.8M | $16.1M | ||
| Q1 25 | $36.1M | $18.9M | ||
| Q4 24 | $37.0M | $24.7M | ||
| Q3 24 | $35.4M | $28.3M | ||
| Q2 24 | $33.3M | $25.8M | ||
| Q1 24 | $33.5M | $22.7M |
| Q4 25 | — | $-554.0K | ||
| Q3 25 | $-2.3M | $-1.8M | ||
| Q2 25 | $-8.8M | $-1.5M | ||
| Q1 25 | $-3.2M | $-1.5M | ||
| Q4 24 | — | $-756.0K | ||
| Q3 24 | $-2.2M | $1.7M | ||
| Q2 24 | $-2.8M | $343.0K | ||
| Q1 24 | $-3.8M | $-1.7M |
| Q4 25 | 49.2% | 21.1% | ||
| Q3 25 | 49.6% | 14.3% | ||
| Q2 25 | 51.9% | 15.6% | ||
| Q1 25 | 50.6% | 16.1% | ||
| Q4 24 | 51.0% | 14.7% | ||
| Q3 24 | 51.6% | 22.0% | ||
| Q2 24 | 56.9% | 17.6% | ||
| Q1 24 | 56.5% | 13.5% |
| Q4 25 | -11.2% | -2.2% | ||
| Q3 25 | -6.4% | -9.9% | ||
| Q2 25 | -28.9% | -8.4% | ||
| Q1 25 | -4.1% | -7.2% | ||
| Q4 24 | 1.3% | -2.1% | ||
| Q3 24 | 0.8% | 6.8% | ||
| Q2 24 | 0.7% | 2.0% | ||
| Q1 24 | -5.3% | -5.8% |
| Q4 25 | — | -3.0% | ||
| Q3 25 | -6.6% | -11.0% | ||
| Q2 25 | -24.6% | -9.3% | ||
| Q1 25 | -8.8% | -8.0% | ||
| Q4 24 | — | -3.1% | ||
| Q3 24 | -6.2% | 5.9% | ||
| Q2 24 | -8.3% | 1.3% | ||
| Q1 24 | -11.3% | -7.6% |
| Q4 25 | $-0.07 | $-0.01 | ||
| Q3 25 | $-0.03 | $-0.05 | ||
| Q2 25 | $-0.10 | $-0.05 | ||
| Q1 25 | $-0.03 | $-0.04 | ||
| Q4 24 | $-0.03 | $-0.02 | ||
| Q3 24 | $-0.02 | $0.04 | ||
| Q2 24 | $-0.03 | $0.01 | ||
| Q1 24 | $-0.04 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.1M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $132.7M | $37.0M |
| Total Assets | $186.0M | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.1M | $10.7M | ||
| Q3 25 | $61.5M | $13.6M | ||
| Q2 25 | $60.5M | $12.5M | ||
| Q1 25 | $59.6M | $11.4M | ||
| Q4 24 | $48.8M | $15.7M | ||
| Q3 24 | $39.2M | $12.3M | ||
| Q2 24 | $53.2M | $11.9M | ||
| Q1 24 | $49.3M | $6.6M |
| Q4 25 | $132.7M | $37.0M | ||
| Q3 25 | $135.7M | $37.0M | ||
| Q2 25 | $131.8M | $30.4M | ||
| Q1 25 | $134.7M | $31.5M | ||
| Q4 24 | $128.2M | $32.6M | ||
| Q3 24 | $119.9M | $29.1M | ||
| Q2 24 | $114.0M | $23.5M | ||
| Q1 24 | $106.5M | $20.6M |
| Q4 25 | $186.0M | $57.1M | ||
| Q3 25 | $186.8M | $57.5M | ||
| Q2 25 | $187.1M | $52.6M | ||
| Q1 25 | $189.2M | $54.0M | ||
| Q4 24 | $173.7M | $59.2M | ||
| Q3 24 | $176.2M | $57.1M | ||
| Q2 24 | $192.9M | $53.0M | ||
| Q1 24 | $184.8M | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.2M | $2.3M |
| Free Cash FlowOCF − Capex | — | $2.2M |
| FCF MarginFCF / Revenue | — | 12.0% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.2M | $2.3M | ||
| Q3 25 | $4.2M | $-1.3M | ||
| Q2 25 | $8.9M | $1.8M | ||
| Q1 25 | $4.8M | $-3.5M | ||
| Q4 24 | $7.4M | $865.0K | ||
| Q3 24 | $3.7M | $4.3M | ||
| Q2 24 | $9.3M | $1.4M | ||
| Q1 24 | $3.5M | $-2.4M |
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% | ||
| Q1 24 | — | -11.1% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | 0.0% | 1.4% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | 0.0% | 1.6% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.0% | 1.1% | ||
| Q1 24 | 0.0% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXFY
Segment breakdown not available.
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
